---
schema_version: "secwatch.filing_event.v1"
accession: "0001516551-24-000052"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2024-04-03T23:59:59+00:00"
generated_at: "2026-06-04T02:49:26.073407+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience reports pro forma equity >$5M after $90M private placement

## Summary
- Closed private placement of 15.7M shares and 10.0M pre-funded warrants for $90M gross ($83.5M net).
- Sold real estate held by subsidiary Avalite Sciences, recording $1.14M gain in pro forma.
- Pro forma stockholders' equity rises to $82.5M from ($2.1M) deficit at Dec 31, 2023.
- Company believes it now meets Nasdaq's $5M minimum equity requirement for initial listing.

## SEC filing metadata
- accession: 0001516551-24-000052
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2024-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000151655124000052/0001516551-24-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000151655124000052/skye-20240403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001516551-24-000052
- JSON: https://secwatch.observer/filing/0001516551-24-000052.json
- Plain text: https://secwatch.observer/filing/0001516551-24-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.